SARS-CoV-2 (COVID-19) Inhibitor screening Kit | EP-105

The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health. Currently, there is no specific treatment for COVID-19. It is urgent to develop the SARS-CoV-2 inhibitors, for example vaccines and therapeutic antibodies and small molecular compounds against COVID-19.

 

This kit is useful for screening inhibitors of SARS-CoV-2.

ELISA Buffer Set-96T (EBS-001) is sold separately and not included in kit, and please contact us if you need the buffer.

 

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

 

Upon receipt, please store all items at -20℃ to -70℃. After reconstitution, the stock solution should be kept at -70℃.

It is recommended not to freeze thaw more than 3 times.

This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of SARS-CoV-2 inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized SARS-CoV-2 S protein RBD and in-house developed biotinylated Human ACE2 protein. This product is uniquely suitable for rapid high-throughput screening of SARS-CoV-2 inhibitors. Briefly, we provide you with a biotinylated Human ACE2 protein, a SARS-CoV-2 S protein RBD protein, an SARS-CoV-2 inhibitor (as method verified Reference), and Streptavidin-HRP reagent.

 

Your experiment will include 4 simple steps:

a) Coat the plate with SARS-CoV-2 S protein RBD.

b) Add 50ul biotinylated human ACE2 to coated plate.

c) Add the reference or your molecule of interest.

d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

Finally, the ability of your compound to inhibit S protein RBD: ACE2 binding will be determined by comparing OD readings among different experimental groups.